Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

被引：305

作者：

Nomura, Sumihiro ^{[1
]}

Sakamaki, Shigeki ^{[1
]}

Hongu, Mitsuya ^{[1
]}

Kawanishi, Eiji ^{[1
]}

Koga, Yuichi ^{[1
]}

Sakamoto, Toshiaki ^{[1
]}

Yamamoto, Yasuo ^{[1
]}

Ueta, Kiichiro ^{[2
]}

Kimata, Hirotaka ^{[2
]}

Nakayama, Keiko ^{[2
]}

Tsuda-Tsukimoto, Minoru ^{[3
]}

机构：

[1] Mitsubishi Tanabe Pharma Corp, Med Chem Res Labs, Toda, Saitama, Japan

[2] Mitsubishi Tanabe Pharma Corp, Pharmacol Res Labs, Toda, Saitama, Japan

[3] Mitsubishi Tanabe Pharma Corp, DMPK Res Labs, Toda, Saitama, Japan

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2010年 / 53卷 / 17期

关键词：

ANTIDIABETIC AGENTS; SGLT2; INHIBITORS; DERIVATIVES; PREVALENCE; REDUCTION; MECHANISM;

D O I：

10.1021/jm100332n

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We discovered that C-glucosides 4 bearing a heteroaromatic ring formed metabolically more stable inhibitors for sodium-dependent glucose cotransporter 2 (SGLT2) than the O-glucoside, 2 (T-1095). A novel thiophene derivative 4b-3 (canagliflozin) was a highly potent and selective SGLT2 inhibitor and showed pronounced anti-hyperglycemic effects in high-fat diet fed KK (HF-KK) mice.

引用

下载

页码：6355 / 6360

页数：6

共 50 条

[1] Discovery of novel C-glucosides with thiophene ring as sodium-dependent glucose cotransporter 2 inhibitors for the treatment of type 2 diabetes mellitus
Nomura, Sumihiro
Sakamaki, Shigeki
Hongu, Mitsuya
Kawanishi, Eiji
Koga, Yuichi
Sakamoto, Toshiaki
Yamamoto, Yasuo
Ueta, Kiichiro
Kimata, Hirotaka
Nakayama, Keiko
Tsuda-Tsukimoto, Minoru
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[2] Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
Lamos, Elizabeth M.
Younk, Lisa M.
Davis, Stephen N.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (06) : 763 - 775
[3] CANAGLIFLOZIN Sodium/Glucose Cotransporter 2 Inhibitor Treatment of Type 2 Diabetes Treatment of Obesity
Chao, E. C.
DRUGS OF THE FUTURE, 2011, 36 (05) : 351 - 357
[4] Discovery of O-spiroketal C-arylglucosides as novel and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Sato, Tsutomu
Kobayashi, Takamitsu
Nishimoto, Masahiro
Taka, Naoki
Ohtake, Yoshihito
Takano, Koji
Yamamoto, Keisuke
Ohmori, Masayuki
Yamaguchi, Marina
Takami, Kyoko
Yeu, Sang-Yong
Ahn, Koo-Hyeon
Matsuoka, Hiroharu
Suzuki, Masayuki
Hagita, Hitoshi
Ozawa, Kazuharu
Yamaguchi, Koji
Kato, Motohiro
Ikeda, Sachiya
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[5] Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Meng, Wei
Ellsworth, Bruce A.
Nirschl, Alexandra A.
McCann, Peggy J.
Patel, Manorama
Girotra, Ravindar N.
Wu, Gang
Sher, Philip M.
Morrison, Eamonn P.
Biller, Scott A.
Zahler, Robert
Deshpande, Prashant P.
Pullockaran, Annie
Hagan, Deborah L.
Morgan, Nathan
Taylor, Joseph R.
Obermeier, Mary T.
Humphreys, William G.
Khanna, Ashish
Discenza, Lorell
Robertson, James G.
Wang, Aiying
Hang, Songping
Wetterau, John R.
Janovitz, Evan B.
Flint, Oliver P.
Whaley, Jean M.
Washburn, William N.
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (05) : 1145 - 1149
[6] Dapagliflozin: A Novel Sodium-Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Shah, Niren K.
Deeb, Wasim E.
Choksi, Rushab
Epstein, Benjamin J.
PHARMACOTHERAPY, 2012, 32 (01): : 80 - 94
[7] Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Zhang, Lingyu
Wang, Yuli
Xu, Huaqiang
Shi, Yongheng
Liu, Bingni
Wei, Qunchao
Xu, Weiren
Tang, Lida
Wang, Jianwu
Zhao, Guilong
MEDICINAL CHEMISTRY, 2014, 10 (03) : 304 - 317
[8] Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes
Nisly, Sarah A.
Kolanczyk, Denise M.
Walton, Alison M.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (04) : 311 - 319
[9] Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus
Calado, Joaquim
IDRUGS, 2009, 12 (12) : 785 - 798
[10] Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes
Li, Yao
Shi, Zongjun
Chen, Lei
Zheng, Suxin
Li, Sheng
Xu, Bo
Liu, Zhenhong
Liu, Jianyu
Deng, Chongyang
Ye, Fei
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (10) : 4173 - 4184

← 1 2 3 4 5 →